Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing

References

• World Health Organization. Global Tuberculosis Report 2021. World Health Organization; 2021.
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2020. World Health Organization; 2020.
   Google Scholar
• Ocheretina O, Escuyer VE, Mabou MM, et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One. 2014;9(3):e90569. doi:10.1371/journal.pone.0090569
   Web of Science ®Google Scholar
• Rafael LL, Raquel MS, Rogelio FA, Miroslava FP, Alejandra-Isabel JG, Paola RTS. Discordant results between genotypic and phenotypic assays (Xpert MTB/RIF vs. BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region. Infect Genet Evol. 2021;96:105142. doi:10.1016/j.meegid.2021.105142.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the Rifamycins (Rifampicin, Rifabutin and Rifapentine). Geneva: World Health Organization; 2021.
   Google Scholar
• World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. World Health Organization; 2018.
   Google Scholar
• Liu D, Huang F, Zhang G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect. 2021;21(6):534–536. doi: 10.1016/j.cmi.2021.09.014
   Web of Science ®Google Scholar
• van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991;29(11):2578–2586. doi:10.1128/jcm.29.11.2578-2586.1991
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia, Spp., and Other Aerobic Actinomycetes. 1st ed. CLSI Supplement M62. Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Jo KW, Lee S, Kang MR, Sung H, Kim MN, Shim TS. Frequency and type of disputed rpoB mutations in Mycobacterium tuberculosis isolates from South Korea. Tuberc Respir Dis. 2017;80(3):270–276. doi:10.4046/trd.2017.80.3.270
   Web of Science ®Google Scholar
• Van Deun A, Aung KJM, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633–2640. doi:10.1128/JCM.00553-13
   PubMed Web of Science ®Google Scholar
• Mvelase NR, Pillay M, Sibanda W, Ngozo JN, Brust JCM, Mlisana KP. rpoB mutations causing discordant rifampicin susceptibility in Mycobacterium tuberculosis: retrospective analysis of prevalence, phenotypic, genotypic, and treatment outcomes. Open Forum Infect Dis. 2019;6(4):ofz065. doi:10.1093/ofid/ofz065
   Web of Science ®Google Scholar
• Miotto P, Cabibbe AM, Borroni E, Degano M, Cirillo DM. Role of disputed mutations in the rpoB Gene in interpretation of automated liquid MGIT culture results for Rifampin susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2018;56(5):e01599–17. doi:10.1128/JCM.01599-17
   Web of Science ®Google Scholar
• Hu P, Zhang H, Fleming J, et al. Retrospective analysis of false-positive and disputed Rifampin resistance Xpert MTB/RIF assay results in clinical samples from a referral hospital in Hunan, China. J Clin Microbiol. 2019;57(4):e01707–18. doi:10.1128/JCM.01707-18
   Web of Science ®Google Scholar
• Berrada ZL, Lin SYG, Rodwell TC, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis. 2016;85(2):177–181. doi:10.1016/j.diagmicrobio.2016.01.019
   PubMed Web of Science ®Google Scholar
• Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol. 2009;47(11):3501–3506. doi:10.1128/JCM.01209-09
   PubMed Web of Science ®Google Scholar
• Lin WH, Lee WT, Tsai HY, Jou R. Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2021;65(7). doi:10.1128/AAC.01573-20
   Web of Science ®Google Scholar
• Huo F, Ma Y, Liu R, et al. Interpretation of discordant rifampicin susceptibility test results obtained using genexpert vs phenotypic drug susceptibility testing. Open Forum Infect Dis. 2020;7(8):ofaa279. doi:10.1093/ofid/ofaa279
   PubMed Web of Science ®Google Scholar
• Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 2010;48(7):2495–2501. doi:10.1128/JCM.00128-10
   PubMed Web of Science ®Google Scholar
• Zetola NM, Shin SS, Tumedi KA, et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by Genexpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014;52(7):2422–2429. doi:10.1128/JCM.02489-13
   PubMed Web of Science ®Google Scholar
• Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181–1182. doi:10.1056/NEJMc1413930
   PubMed Web of Science ®Google Scholar
• Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol. 2014;52(6):1846–1852. doi:10.1128/JCM.03005-13
   PubMed Web of Science ®Google Scholar
• Vincent V, Rigouts L, Nduwamahoro E, et al. The TDR tuberculosis strain bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012;16(1):24–31. doi:10.5588/ijtld.11.0223
   Web of Science ®Google Scholar
• Andres S, Hillemann D, Rüsch-Gerdes S, Richter E. Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother. 2014;58(1):590–592. doi:10.1128/AAC.01752-13
   Web of Science ®Google Scholar
• Rigouts L, Gumusboga M, de Rijk WB, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013;51(8):2641–2645. doi:10.1128/JCM.02741-12
   PubMed Web of Science ®Google Scholar